FocusOn Healthcare
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology
  • Resource Centers:
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology

Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma

  • Current Opinion in Urology
  • January 2025
Urothelial Cancer Awareness Month Home Page

Read Full Article

Abstract

Purpose of review

The purpose of this review is to summarize the most recent evidence on surgical management, strategies to reduce tumor recurrence, and surveillance regimens in patients diagnosed with upper tract urothelial carcinoma (UTUC) and elected for radical treatment.

Recent findings

Minimally invasive surgery is gaining momentum in the surgical management of UTUC. Chemoprophylaxis is still the gold standard to reduce intravesical recurrence after radical nephroureterectomy (RNU). Novel surveillance strategies have been proposed to adapt follow-up regimens to patients’ characteristics.

Summary

Minimally invasive surgery has been associated with comparable oncological outcomes to the open approach while improving postoperative morbidity. In these cases, bladder cuff excision (BCE) is mostly performed by an extravesical approach, that demonstrates a noninferiority compared to the intravesical one in terms of oncological outcomes. Although lymphadenectomy is recommended in patients with high-risk tumors, its benefits are still unclear. Currently, there is a lack of recent prospective trials on chemoprophylaxis to reduce intravesical recurrence post RNU, making single-dose postoperative chemotherapy instillation the standard treatment. Although novel risk stratification models were released by international urological guidelines, their validity is mainly nonevidence-based. Risk-adapted follow-up strategies incorporating cystoscopy and cross-sectional imaging accounting for individual patient factors should be implemented.

You might also like:

The biologic landscape and therapeutic implications of upper tract urothelial cancer

Germline genetic variants in cancers of the urothelial tract and association with outcomes

Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI).

Utilization of neoadjuvant chemotherapy (NAC) and pathologic outcomes in upper tract urothelial carcinoma (UTUC).

Share

Modal body text goes here.

FocusOn logo
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More